Joseph K. Burns

Joseph K. Burns

Auto-generated profile, based on publicly available information

Joseph K. Burns

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2011 in Nature
Verified
Journal Article
Closed access
CBCaroline J. Breitbach
Caroline J. Breitbach
JBJames Burke
James Burke
DJDerek Jonker
Derek Jonker
JSJoe Stephenson
Joe Stephenson
AHAndrew R. Haas
Andrew R. Haas
DKDavid H. Kirn
David H. Kirn

1 April 2012 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
KPKelley A Parato
Kelley A Parato
CBCaroline J Breitbach
Caroline J Breitbach
FBFabrice Le Boeuf
Fabrice Le Boeuf
JWJiahu Wang
Jiahu Wang
CSChris Storbeck
Chris Storbeck
JBJohn C Cameron Bell
John C Cameron Bell
Oncolytic viruses are generally designed to be cancer selective on the basis of a single genetic mutation. JX-594 is a thymidine kinase (TK) gene-inactivated oncolytic vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) and lac-Z transgenes that is designed to destroy cancer cells through replication-dependent cell lysis and stimulation of antitumoral immunity. JX-594 has demonstrated a favorable safety profile and reproducible tumor necrosis in a variety of solid cancer types in clinical trials. However, the mechanism(s) responsible for its cancer-selectivity have not yet been well described. We analyzed the replication of JX-594 in three model systems: primary normal and cancer cells, surgical explants, and murine tumor models. JX-594 replication, transgene expression, and cytopathic effects were highly cancer-selective, and broad spectrum activity was demonstrated. JX-594 cancer-selectivity was multi-mechanistic; replication was activated by epidermal growth factor receptor (EGFR)/Ras pathway signaling, cellular TK levels, and cancer cell resistance to type-I interferons (IFNs). These findings confirm a large therapeutic index for JX-594 that is driven by common genetic abnormalities in human solid tumors. This appears to be the first description of multiple selectivity mechanisms, both inherent and engineered, for an oncolytic virus. These findings have implications for oncolytic viruses in general, and suggest that their cancer targeting is a complex and multifactorial process.

22 December 2016 in Current Molecular Medicine
Verified
Journal Article
Closed access
LNL. A. Nash
L. A. Nash
JBJ. K. Burns
J. K. Burns
JCJ. Warman Chardon
J. Warman Chardon
RKR. Kothary
R. Kothary
RPR. J. Parks
R. J. Parks
Spinal muscular atrophy (SMA) is the most common genetically inherited neurodegenerative disease resulting in infant mortality. SMA is caused by genetic deletion or mutation in the survival of motor neuron 1 (SMN1) gene, which results in reduced levels of the survival of motor neuron (SMN) protein. SMN protein deficiency preferentially affects α- motor neurons, leading to their degeneration and subsequent atrophy of limb and trunk muscles, progressing to death in severe forms of the disease. More recent studies have shown that SMN protein depletion is detrimental to the functioning of other tissues including skeletal muscle, heart, autonomic and enteric nervous systems, metabolic/endocrine (e.g. pancreas), lymphatic, bone and reproductive system. In this review, we summarize studies discussing SMN protein's function in various cell and tissue types and their involvement in the context of SMA disease etiology. Taken together, these studies indicate that SMA is a multi-organ disease, which suggests that truly effective disease intervention may require body-wide correction of SMN protein levels.

18 November 2021 in Health Information & Libraries Journal
Verified
Journal Article
Closed access
PDF file
JBJoseph K. Burns
Joseph K. Burns
CECole Etherington
Cole Etherington
OCOlivia Cheng‐Boivin
Olivia Cheng‐Boivin
SBSylvain Boet
Sylvain Boet

24 October 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LNLeslie A. Nash
Leslie A. Nash
EMEmily R. McFall
Emily R. McFall
APAmanda M. Perozzo
Amanda M. Perozzo
MTMaddison Turner
Maddison Turner
KPKathy L. Poulin
Kathy L. Poulin
RPRobin Parks
Robin Parks
Spinal muscular atrophy (SMA) is caused by homozygous mutation of the survival motor neuron 1 (SMN1) gene. Disease severity inversely correlates to the amount of SMN protein produced from the homologous SMN2 gene. We show that SMN protein is naturally released in exosomes from all cell types examined. Fibroblasts from patients or a mouse model of SMA released exosomes containing reduced levels of SMN protein relative to normal controls. Cells overexpressing SMN protein released exosomes with dramatically elevated levels of SMN protein. We observed enhanced quantities of exosomes in the medium from SMN-depleted cells, and in serum from a mouse model of SMA and a patient with Type 3 SMA, suggesting that SMN-depletion causes a deregulation of exosome release or uptake. The quantity of SMN protein contained in the serum-derived exosomes correlated with the genotype of the animal, with progressively less protein in carrier and affected animals compared to wildtype mice. SMN protein was easily detectable in exosomes isolated from human serum, with a reduction in the amount of SMN protein in exosomes from a patient with Type 3 SMA compared to a normal control. Our results suggest that exosome-derived SMN protein may serve as an effective biomarker for SMA.

1 September 2016 in Neuromuscular Disorders
Verified
Journal Article
Open access
JBJoseph K. Burns
Joseph K. Burns
RKRashmi Kothary
Rashmi Kothary
RPRobin Parks
Robin Parks
Spinal muscular atrophy (SMA) is the most common genetically inherited neurodegenerative disease that leads to infant mortality worldwide. SMA is caused by genetic deletion or mutation in the survival of motor neuron 1 (SMN1) gene, which results in a deficiency in SMN protein. For reasons that are still unclear, SMN protein deficiency predominantly affects α-motor neurons, resulting in their degeneration and subsequent paralysis of limb and trunk muscles, progressing to death in severe cases. Emerging evidence suggests that SMN protein deficiency also affects the heart, autonomic nervous system, skeletal muscle, liver, pancreas and perhaps many other organs. Currently, there is no cure for SMA. Patient treatment includes respiratory care, physiotherapy, and nutritional management, which can somewhat ameliorate disease symptoms and increase life span. Fortunately, several novel therapies have advanced to human clinical trials. However, data from studies in animal models of SMA indicate that the greatest therapeutic benefit is achieved through initiating treatment as early as possible, before widespread loss of motor neurons has occurred. In this review, we discuss the merit of carrier and perinatal patient screening for SMA considering the efficacy of emerging therapeutics and the physical, emotional and financial burden of the disease on affected families and society.